8-K: Pyxis Oncology Announces First Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology reported its Q1 2025 financial results and provided a business update, highlighting progress with its lead candidate, micvotabart pelidotin (MICVO), and upcoming data milestones.

Summary

• Pyxis Oncology reported its financial results for the quarter ended March 31, 2025, and provided a business update on May 15, 2025.
• The company is developing next-generation ADC therapeutics for difficult-to-treat cancers.
• Preclinical data supports the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO), driving anti-tumor activity via direct tumor killing, bystander effect, and immunogenic cell death.
• Preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy is expected in the second half of 2025.
• Preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy is expected in the first half of 2026.
• Preliminary data from the Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients is expected in the second half of 2025.
• As of March 31, 2025, Pyxis Oncology had $106.9 million in cash and cash equivalents, including restricted cash, and short-term investments.
• The company believes its current funds will be sufficient to fund operations into the second half of 2026.
• Research and development expenses were $17.0 million for the quarter ended March 31, 2025, compared to $13.0 million for the quarter ended March 31, 2024.
• General and administrative expenses were $5.9 million for the quarter ended March 31, 2025, compared to $8.2 million for the quarter ended March 31, 2024.
• Net loss was $21.2 million, or ($0.35) per common share, for the quarter ended March 31, 2025, compared to $3.3 million, or ($0.06) per common share, for the quarter ended March 31, 2024.
• As of May 14, 2025, the outstanding number of shares of Common Stock of Pyxis Oncology was 61,947,665.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it has a strong cash position, is making progress with its lead candidate, and has multiple upcoming data milestones.

Positives

• MICVO demonstrated broad anti-tumor activity across ten solid tumor indications in PDX models.
• Combining a mouse analog of MICVO with anti-PD-1 therapy inhibited EMT6 tumor growth and improved survival.
• General and administrative expenses decreased to $5.9 million for the quarter ended March 31, 2025, compared to $8.2 million for the quarter ended March 31, 2024, due to lower stock-based compensation costs, lower corporate insurance costs and decrease in legal, professional and consulting fees.
• MICVO was well-tolerated with a low discontinuation rate in the Phase 1 Part 1 dose escalation study.
• The company has a strong balance sheet with $107M cash runway into 2H 2026.

Negatives

• Net loss increased to $21.2 million, or ($0.35) per common share, for the quarter ended March 31, 2025, compared to $3.3 million, or ($0.06) per common share, for the quarter ended March 31, 2024.
• Research and development expenses increased to $17.0 million for the quarter ended March 31, 2025, compared to $13.0 million for the quarter ended March 31, 2024.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• The company's success depends on the successful development and commercialization of its product candidates, including micvotabart pelidotin.
• Clinical trials may be delayed or fail to obtain regulatory approvals.
• The company relies on third parties and collaborators to conduct clinical trials, manufacture their product candidates, and develop and commercialize their product candidates.
• The company faces competition from other drug candidates.

Future Outlook

The company expects to report preliminary data from its ongoing Phase 1 trials evaluating MICVO as a monotherapy and in combination with pembrolizumab later this year and believes its current cash will fund operations into the second half of 2026.

Management Comments

• We are enthusiastic about the progress we are making with micvotabart pelidotin, particularly our recent preclinical data that validate its unique three-pronged mechanism of action and indicate that MICVO monotherapy may be eliciting immune responses in previously unresponsive tumors, said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology.
• Our focus remains on delivering durable and efficacious therapies for patients with recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors, building on the tremendous potential of our next generation ADC.

Industry Context

Pyxis Oncology is focused on developing next-generation ADC therapeutics, a competitive field with significant potential for treating difficult-to-treat cancers, particularly in the recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) space where there is a high unmet medical need.

Comparison to Industry Standards

• The company's lead candidate, micvotabart pelidotin (MICVO), is being developed as a potential treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), a disease with a poor prognosis and limited treatment options.
• Current standard of care for R/M HNSCC includes immunotherapy (IO) + chemo in 1L, with overall survival dropping to <7 months in 2L, highlighting the need for new treatment options.
• The company's approach of targeting EDB+FN, a non-cellular structural component of the extracellular matrix (ECM), is a novel approach compared to traditional ADCs that target cell surface antigens.
• Other companies developing ADCs for solid tumors include Seagen (Adcetris), Immunomedics (Trodelvy), and Daiichi Sankyo (Enhertu), but Pyxis Oncology's extracellular targeting approach differentiates it from these competitors.
• The company's collaboration with Merck to evaluate MICVO in combination with pembrolizumab is a common strategy in the oncology field, as combination therapies can often improve efficacy compared to monotherapy.

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will impact shareholder value.
• Patients: The development of new cancer therapies could provide new treatment options for patients with difficult-to-treat cancers.
• Employees: The company's progress and financial stability impact employee job security and opportunities.

Next Steps

• Report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in the second half of 2025.
• Report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in the first half of 2026.
• Report preliminary data from the Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients in the second half of 2025.
• Select a dose of MICVO in the ongoing Phase 1/2 combination study of micvotabart pelidotin and Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors by mid-year 2025.

Key Dates

Keywords

Pyxis Oncology, micvotabart pelidotin, ADC, HNSCC, pembrolizumab, clinical trial, financial results, oncology